{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=4", "query": { "intervention": "HAV", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1228, "total_pages": 123, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HAV&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T07:17:54.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01590641", "title": "A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis B", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatitis B", "HBV" ], "interventions": [ { "name": "Single Ascending Dose (SAD) Cohorts GS-9620", "type": "DRUG" }, { "name": "Multiple Ascending Dose (MAD) Cohorts", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 49, "start_date": "2012-04", "completion_date": "2013-10", "has_results": false, "last_update_posted_date": "2013-11-14", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 13, "location_summary": "Phoenix, Arizona • Costa Mesa, California • San Diego, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01590641" }, { "nct_id": "NCT01368497", "title": "Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis B" ], "interventions": [ { "name": "Entecavir and peginterferon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "3 Years to 18 Years" }, "enrollment_count": 60, "start_date": "2012-09", "completion_date": "2016-12-23", "has_results": true, "last_update_posted_date": "2022-05-26", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 6, "location_summary": "San Francisco, California • Baltimore, Maryland • Minneapolis, Minnesota + 3 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01368497" }, { "nct_id": "NCT00031070", "title": "Increasing HAART-Induced Immune Restoration With Cyclosporine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Abacavir sulfate, Lamivudine and Zidovudine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Hepatitis A Vaccine (Inactivated)", "type": "BIOLOGICAL" }, { "name": "Efavirenz", "type": "DRUG" }, { "name": "Pneumococcal Conjugate Vaccine, Heptavalent", "type": "BIOLOGICAL" }, { "name": "Rabies Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": null, "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2015-03-09", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 15, "location_summary": "Sacramento, California • Miami, Florida • Chicago, Illinois + 8 more", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00031070" }, { "nct_id": "NCT04804072", "title": "INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections", "Drug Use", "Opioid Use", "Opioid-use Disorder" ], "interventions": [ { "name": "Medication for opioid-use disorder (MOUD) for opioid-use disorder (OUD)", "type": "DRUG" }, { "name": "HIV testing", "type": "DIAGNOSTIC_TEST" }, { "name": "HIV treatment for participants living with HIV not already in care", "type": "DRUG" }, { "name": "PrEP for participants without HIV", "type": "DRUG" }, { "name": "Testing and referral for vaccination or treatment for hepatitis A virus (HAV) and hepatitis B virus (HBV)", "type": "DIAGNOSTIC_TEST" }, { "name": "Testing and referral for treatment for hepatitis C virus (HCV)", "type": "DIAGNOSTIC_TEST" }, { "name": "Sexually transmitted infection (STI) testing and treatment", "type": "DIAGNOSTIC_TEST" }, { "name": "Primary care", "type": "OTHER" }, { "name": "Harm reduction services", "type": "BEHAVIORAL" }, { "name": "Peer navigation", "type": "BEHAVIORAL" }, { "name": "COVID-19 testing and referral for further evaluation, care and/or treatment", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "OTHER", "BEHAVIORAL" ], "sponsor": "HIV Prevention Trials Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 447, "start_date": "2021-06-02", "completion_date": "2024-12-17", "has_results": true, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 5, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • The Bronx, New York + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "The Bronx", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04804072" }, { "nct_id": "NCT01384383", "title": "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 248, "start_date": "2011-08", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384383" }, { "nct_id": "NCT01054573", "title": "VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Telaprevir", "type": "DRUG" }, { "name": "pegylated interferon (Peg-IFN) alfa-2a", "type": "DRUG" }, { "name": "ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Infectious Diseases BVBA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 90, "start_date": "2010-04", "completion_date": "2012-05", "has_results": true, "last_update_posted_date": "2013-05-08", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 14, "location_summary": "Coronado, California • Los Angeles, California • San Francisco, California + 11 more", "locations": [ { "city": "Coronado", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01054573" }, { "nct_id": "NCT03146741", "title": "Zepatier For Treatment Of Hepatitis C-Negative Patients Who Receive Heart Transplants From Hepatitis C-Positive Donors (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Zepatier", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2017-05-16", "completion_date": "2019-11-30", "has_results": true, "last_update_posted_date": "2021-11-22", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03146741" }, { "nct_id": "NCT02511431", "title": "Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis D" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2015-07-29", "completion_date": "2017-02-23", "has_results": true, "last_update_posted_date": "2018-09-25", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02511431" }, { "nct_id": "NCT01441180", "title": "GS-7977 With Ribavirin for Hepatitis C (SPARE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "GS7977", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2011-09", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2014-09-26", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01441180" }, { "nct_id": "NCT02825212", "title": "Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Hepatitis C", "Cryoglobulinemia" ], "interventions": [ { "name": "Harvoni", "type": "DRUG" }, { "name": "Epclusa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 10, "start_date": "2016-02", "completion_date": "2019-07-19", "has_results": true, "last_update_posted_date": "2020-12-17", "last_synced_at": "2026-10-21T07:17:54.721Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02825212" } ] }